Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591716 | 0.83 | ESR1 (0.44) | L3MBTL1SIGMAR1ESR1MMP8KCNH2 | |
| SCHEMBL24784249 | 0.80 | SIGMAR1 (0.43) | L3MBTL1SIGMAR1ESR1S1PR2S1PR1 | |
| SCHEMBL15511629 | 0.80 | L3MBTL1 (0.64) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL14178223 | 0.79 | MEN1 (0.74) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL15511313 | 0.78 | SIGMAR1 (0.66) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL18551667 | 0.78 | L3MBTL1 (0.67) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL30229979 | 0.78 | L3MBTL1 (0.67) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL17703303 | 0.77 | HTR1B (0.58) | L3MBTL1MEN1KMT2AESR1 | |
| SCHEMBL6849740 | 0.76 | TAAR1 (0.73) | L3MBTL1SIGMAR1MEN1KMT2ATAAR1 | |
| SCHEMBL21367140 | 0.76 | MAOA (0.54) | SIGMAR1ESR1TAAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | L3MBTL1 2900/4885SIGMAR1 1756/4885MEN1 1676/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | L3MBTL1 479/4885SIGMAR1 2774/4885MEN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.